OSE — Ose Immunotherapeutics SA Cashflow Statement
0.000.00%
Last trade - 00:00- €124.89m
- €154.27m
- €83.44m
- 66
- 88
- 39
- 75
Annual cashflow statement for Ose Immunotherapeutics SA, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | PRESS |
| Standards: | IFRS | IFRS | IFRS | IFRS | — |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -16.6 | -16.9 | -17.8 | -23 | 37.4 |
| Depreciation | |||||
| Non-Cash Items | -0.481 | 3.58 | -0.652 | 0.87 | 8.38 |
| Other Non-Cash Items | |||||
| Changes in Working Capital | -2.97 | 0.693 | -3.38 | -1.05 | -3.64 |
| Net Change in Other Assets & Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -19.3 | -9.92 | -18.3 | -19.8 | 48.4 |
| Capital Expenditures | -0.21 | -0.472 | -0.274 | -0.232 | -0.077 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -0.294 | -0.355 | 0.3 | -0.275 | -46.8 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Change in Net Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -0.504 | -0.827 | 0.026 | -0.507 | -46.9 |
| Financing Cash Flow Items | -0.274 | — | — | 0.3 | -0.469 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 23.3 | 15 | 10.3 | 13.3 | -3.46 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 3.53 | 4.21 | -7.96 | -6.95 | -1.93 |